HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Pharming (NASDAQ:PHAR) and maintained a $37 price target.
May 31, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Pharming and maintained a $37 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $37 price target by a reputable analyst suggests positive sentiment and confidence in Pharming's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100